The FDA’s top regulator just quit after the White House forced him to approve flavored e-cigarettes he opposed, exposing a stunning power grab that threatens the agency’s independence and public health safeguards.
Quick Take
- FDA Commissioner Marty Makary resigned Tuesday after clashing with President Trump over approving flavored e-cigarettes from Glas Inc., signaling White House override of agency independence
- Internal tensions escalated over mifepristone abortion pill delays and accusations of micromanaging, with career staff leaking criticisms of Makary’s leadership style
- Deputy Commissioner Kyle Diamantas assumed acting role immediately, with Trump praising Makary publicly while the resignation suggests forced departure over policy disputes
- The departure signals Trump administration prioritization of deregulation and industry interests over career FDA processes, setting precedent for executive interference in health decisions
When Political Pressure Overrides Science
Marty Makary’s tenure as FDA Commissioner lasted barely sixteen months, ending in a resignation that exposes the fragility of regulatory independence under political pressure.
The Johns Hopkins surgeon, appointed in early 2025 as part of HHS Secretary Robert F. Kennedy Jr.’s health agency overhaul, found himself caught between his mandate to protect public health and direct White House demands to approve products he believed posed youth risks.
The breaking point came over flavored e-cigarettes, a category the FDA had restricted to prevent nicotine addiction among teenagers, a crisis that peaked in 2019 when nearly 28 percent of high school students reported vaping.
The Vaping Approval That Started the Unraveling
On May 6, the FDA approved flavored e-cigarettes from Glas Inc. following what sources describe as Trump’s personal intervention in the regulatory process. Makary reportedly resisted the approval, viewing it as contradictory to public health evidence on youth addiction patterns.
This wasn’t a subtle policy disagreement handled through normal channels; Trump’s involvement signaled that industry lobbying had found a direct path to the Oval Office, bypassing the scientific review process that legitimizes FDA decisions. The approval stood, but Makary’s position became untenable once he realized the administration would override his authority on core regulatory matters.
Abortion Pills and the Culture War Collision
Tensions extended beyond vaping into abortion politics. Conservative groups, including Susan B. Anthony Pro-Life America, had demanded Makary’s removal over delays in reviewing mifepristone, the abortion pill. HHS Secretary Kennedy tasked Makary with conducting a review scheduled for June 2025, but the timeline slipped amid internal disagreements.
Anti-abortion advocates viewed these delays as Makary protecting access to the drug rather than conducting legitimate scientific review. This culture war dimension transformed what could have been a routine regulatory disagreement into a litmus test of political loyalty, further isolating Makary within an administration that increasingly viewed FDA independence as obstruction.
US FDA Commissioner Marty Makary resigned, President Trump said, after weeks of clashing with top White House and health advisers and drawing scrutiny for a series of controversial decisions, according to several people familiar with internal dynamics https://t.co/NumUuKkfFJ pic.twitter.com/HhmdfGW1J9
— Reuters Health (@Reuters_Health) May 12, 2026
Leadership Style Becomes a Liability
Beyond policy disputes, anonymous FDA career staff criticized Makary’s management approach, describing his leadership as unprecedented micromanaging and claiming he announced decisions via press releases rather than through proper channels, eroding institutional trust.
These leaks suggest internal resentment ran deep, with staff viewing him as more interested in self-promotion than protecting agency independence.
Whether these criticisms reflect legitimate governance concerns or reflect resistance to his reform agenda remains unclear, but they provided political cover for his departure by shifting the narrative from policy disagreement to management failure.
The "Vape Man" bights the dust.
Marty Makary resigns as FDA commissioner following industry and White House backlash https://t.co/P5ToUBYeho— Danthegeeman Tvvitter jail bird Subtard (@danthegeeman) May 12, 2026
The Resignation That Wasn’t Voluntary
Trump’s public framing of Makary’s departure as amicable masks the underlying reality: the President’s office had decided the Commissioner’s resistance to industry-friendly deregulation was incompatible with administration goals.
Trump posted on Truth Social that Makary was “having some difficulty,” a characterization that softens what sources confirm was a forced exit over the e-cigarette dispute.
Makary’s resignation statement calling his tenure an “honor of a lifetime” reads as diplomatic language for a professional exit under pressure, not a voluntary decision to pursue other opportunities.
What Comes Next for FDA Independence
Kyle Diamantas, Trump’s Deputy Commissioner for Food, assumes the acting role with a mandate to accelerate deregulation. Unlike Makary, Diamantas carries no reputation for resisting White House pressure, suggesting the administration selected him precisely for his alignment with Trump’s pro-industry stance.
This transition signals that FDA independence, already weakened under RFK Jr.’s HHS leadership, will erode further as career staff recognize that resistance to political directives carries career consequences. The precedent established here extends beyond vaping: any future FDA Commissioner who prioritizes scientific evidence over executive preference now knows the job is temporary.
Sources:
Makary’s time atop FDA over, Diamantas named acting commissioner
Trump says Dr. Marty Makary will leave role as FDA commissioner
FDA Commissioner Marty Makary to resign, capping turbulent tenure
